The latest headlines across every section, pulled from official and open-access sources.
January - March 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
July - September 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
April - June 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
October - December 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
January - March 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
April - June 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
July - September 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Human-to-human hantavirus transmission: incubation, infectious period, asymptomatic or presymptomatic transmission and transmission routes.
January - March 2021 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
October - December 2020 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Patients who underwent mitral transcatheter edge-to-edge repair (M-TEER) with an optimal result were more likely to have improved hemodynamics and less likely to experience major adverse events, all-cause mortality, heart failure (HF) hospitalization or reintervention at one year...
April – June 2015 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
July – September 2015 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
January - March 2025 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
April - June 2025 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
July - September 2025 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
LANCASTER, Ohio (June 12, 2026) — Fry Pie Factory has issued a voluntary recall of its 5 ounce Pepperoni Rolls due to misbranding involving undeclared milk, a known allergen, and a process deviation related to refrigeration.
Dexcom, Abbott, MiniMed and Insulet featured upcoming technologies at the American Diabetes Association’s annual event. Catch up on news coming out of the conference.
The stroke treatment could contribute about $100 million in incremental revenue over time to Boston Scientific, the buyer of Penumbra, one analyst said.
For Physicians: A Guide to Non-emergency Single Patient Expanded Access Submissions webpage describes the four initial steps to initiating a request for single patient expanded access in a non-emergency situation. Subsequent submissions are also described. Links are available for more information.
Information is intended to provide an overview of timelines applicable to physicians who plan to submit or have submitted individual patient expanded access applications for emergency use.
IND Application Reporting: Safety Reports
The Office of Generic Drugs requested manufacturers of sixteen look-alike name pairs to voluntarily revise the appearance of their established names in order to minimize medication errors resulting from look-alike confusion.